van der Wall SJ, Teutsch C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, Franca LR, Lu S, Lip GYH, Huisman MV, GLORIA-AF Investigators. Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF. TH Open. 2021 Feb 6;5(1):e35-42. doi: 10.1055/s-0040-1722706
van den Dries CJ, van Doorn S, Souverein P, Pajouheshnia R, Moons KGM, Hoes AW, Gerrsing G-J, van den Ham HA. The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation. TH Open. 2020 Dec 23;4(4):e417-26. doi: 10.1055/s-0040-1721499
Van Hout B, Hawe E, Cohen AT. Impact of patient characteristics on treatment outcomes in symptomatic venous thromboembolism: results of HOKUSAI-VTE randomized trial analysis. TH Open. 2020 Sep 23;4(3):e245-54. doi: 10.1055/s-0040-1716496
Skajaa N, Horvath-Puho E, Adelborg K, Prandoni P, Rothman KJ, Sorensen HT. Venous thromboembolism in Denmark: seasonality in occurrence and mortality. TH Open. 2019 Jun 18;3(2):e171-9. doi: 10.1055/s-0039-1692399.
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Sharp L, Donnelly D, Hegarty A, Carsin AE, Deady S, McCluskey N, Gavin A, Comber H. Risk of several cancers is higher in urban areas after adjusting for socioeconomic status. Results from a two-country population-based study of 18 common cancers. J Urban Health. 2014 Jun;91(3):510-25. doi: 10.1007/s11524-013-9846-3
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.